HeyJaredOn The Pen GLP-1 News
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.
- Indexed episodes, last 90 days
- 12
- Latest publication
- Sep 15, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 8, 2026
Latest episodes
17% Weight Loss in 16 Weeks… Is This Better Than Retatrutide? (opens the original)
Read excerpt
Lilly just gave us a glimpse of what could come after today’s GLP-1s, and it may not be about simply pushing patients to stronger drugs and higher doses. This week on On The Pen: The Weekly Dose, we break down Lilly’s surprising early data combining just 5 mg of tirzepatide with 3 mg of eloralintide, producing roughly 17% weight loss in only 16 weeks. Could combinations like this eventually approach retatrutide-level efficacy with better tolerability? And when retatrutide reaches the real world,
GLP-1 for 6 Year Olds? Here’s What the Trial Actually Found (opens the original)
Read excerpt
Is obesity still a disease worthy of treatment when the patient is six years old? This week, Novo Nordisk released Phase 3 STEP Young data in children ages 6 to 11 with obesity. After 68 weeks, 40.4% of children treated with semaglutide moved below the obesity threshold, compared with 0% on placebo. More than 85% of the children entered the trial with class II or class III severe obesity, and both groups received lifestyle intervention. That raises a harder question than whether people are comfo
We’re Solving Obesity. Now Who Pays for It? (opens the original)
Read excerpt
This week on On The Pen, the GLP-1 story is moving in two very different directions. The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its consumer guidance around compounded GLP-1 medications and multi-dose vials, and employers continue questioning whether they can afford obesity-drug coverage. At the same time, the medical case for these medications keeps getting stronger. We break down Mounjaro’s new cardiovascular indication and what
GLP-1 Coverage Is COLLAPSING in 2027 (opens the original)
Read excerpt
GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health. In this episode of the On The Pen Podcast, Dave Knapp breaks down two of the biggest GLP-1 stories of the week: why most states are opting out of the Trump administration’s new Medicaid obesity-drug coverage model, and why employers are preparing to cut GLP-1 coverage in 2027. We also dig into the growing conversation around GLP-1 microdosing after Real Hous
$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold” (opens the original)
Read excerpt
Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America. But getting there may depend on something most patients have never heard of: the global peptide manufacturing supply chain. In this episode of The Weekly Dose from On The Pen, Dave Knapp, Man on the Mounjaro, breaks down one of the biggest weeks in GLP-1 and obesity medicine news, including the surprising
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.